Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window

NCT01221246 is registered in ClinicalTrials.gov with Genervon Biopharmaceuticals, LLC as lead sponsor.

NCT NCT01221246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01221246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window
Lead sponsor
Genervon Biopharmaceuticals, LLC
Phase
Phase 2
Overall status
Completed
Start date
March 8, 2011
Completion date
July 7, 2016
Enrollment
34 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

stroke